Articles tagged "Primary sclerosing cholangitis"

2017 American Transplant Congress
Graft and Patient Survival in Liver Transplantation for Primary Sclerosing Cholangitis with Organs from DCD versus DBD Donors: Analysis of the UNOS Database.
O. Mousa,¹ J. Corral,¹ M. Pang,¹ D. Lee,² J. Nguyen,² K. Croome,² D. Harnois.²
¹Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL; ²Transplant, Mayo Clinic, Jacksonville, FL
Background: Primary sclerosing cholangitis (PSC) remains a major indication for liver transplantation (LT) worldwide. In an era of limited organ donation pool, assessment of PSC…
2016 American Transplant Congress
Tumor-Necrosis-Factor-α Antagonist Therapy for Inflammatory Bowel Disease After Liver Transplantation.
R. Parekh, M. Segovia, N. Kaur.
Gastroenterology and Hepatology, Henry Ford Hospital, Detroit, MI.
Background:The safety and effectiveness of tumor-necrosis-factor-α antagonist (anti-TNF-α) therapy for inflammatory bowel disease (IBD) has not been well-established in patients after liver transplantation (LT). We…
2015 American Transplant Congress
Early Recurrence of Primary Sclerosing Cholangitis After Liver Transplantation Has No Negative Impact on Patients outcome'
B. Lowry,¹ W. El Moghazy,^1,2 G. Meeberg,¹ N. Kneteman.¹
¹Hepatobiliary Pancreatic Surgery and Transplantation, University of Alberta, Edmonton, AB, Canada; ²Surgery, Sohag University, Sohag, Egypt.
Liver transplantation (LT) is the only therapeutic option for primary sclerosing cholangitis (PSC), however, recurrence of PSC (rPSC) post-LT occurs at rates ranging from 9-47%.…